DelveInsight's “Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Chronic Spontaneous Urticaria Market with DelveInsight's In-Depth Report @ Chronic Spontaneous Urticaria Market Size
Key Takeaways from the Chronic Spontaneous Urticaria Market
- In November 2024:- Celldex Therapeutics- The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
- In November 2024:- Escient Pharmaceuticals Inc.- Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU). Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
- In November 2024:- Jemincare- A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines
- In November 2024:- Jasper Therapeutics Inc.- A Phase 1B/2A, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With, Or Who Cannot Tolerate Omalizumab.
- In November 2024:- Novartis Pharmaceuticals- The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
- According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of chronic spontaneous urticaria were approximately 2.8 million among the 7MM in 2023 which is expected to change during the forecast period (2024-2034).
- In the US, there were approximately 521 thousand diagnosed prevalent cases of chronic spontaneous urticaria in 2023 which was nearly 19% of the total 7MM.
- Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of chronic spontaneous urticarial in 2023 with approximately 327 thousand cases followed by France with nearly 255 thousand cases. On the other hand, Spain accounted for the least with approximately 163 thousand cases.
- In 2023, Japan accounted for the highest diagnosed prevalent cases of chronic spontaneous urticaria with approximately 1 million cases.
- Among the age-specific diagnosed prevalent cases of chronic spontaneous urticaria in the US, there were approximately 47 thousand, 80 thousand, 72 thousand, 81 thousand, 86 thousand, and 156 thousand cases in the age groups <18, 18−29, 30−39, 40−49, 50−59, and ≥60, respectively, in 2023.
- There were approximately 391 thousand male and 839 thousand female cases of chronic spontaneous urticarial among EU4 and the UK in 2023.
- In Japan, there were approximately 46 thousand mild cases, 690 thousand moderate cases, and 326 thousand severe cases of chronic spontaneous urticaria in 2023.
- The leading Chronic Spontaneous Urticaria Companies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
- Promising Chronic Spontaneous Urticaria Therapies such as barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
Stay ahead in the Chronic Spontaneous Urticaria Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Spontaneous Urticaria Market Outlook
Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM
- Total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases
- Chronic Spontaneous Urticaria Type-specific Cases
- Chronic Spontaneous Urticaria Gender-specific Cases
- Chronic Spontaneous Urticaria Age-specific Cases
- Chronic Spontaneous Urticaria Severity-specific Cases
Download the report to understand which factors are driving Chronic Spontaneous Urticaria epidemiology trends @ Chronic Spontaneous Urticaria Prevalence
Chronic Spontaneous Urticaria Treatment Market
The treatment of CSU is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a step-wise approach, starting with first-line treatments and progressing to more advanced options if necessary. Treatment is generally initiated with nonsedating antihistamines in the daytime and sedating antihistamines at night. H2-antihistamines are often combined with H1 to achieve better symptom control in CSU and are added if individuals complain of indigestion or acidity. The most commonly used H2 antihistamine for CSU is ranitidine. However, it is important to note that ranitidine has been withdrawn from many markets due to safety concerns. Many patients, however, do not achieve symptom control, with only less than half of patients responding to H1-antihistamines at standard doses. Adverse effects such as somnolence can occur in susceptible individuals, increasing the treatment burden, despite increasing the dose.
Chronic Spontaneous Urticaria Marketed Drugs
- XOLAIR (omalizumab): Roche/Novartis
- DUPIXENT (dupilumab): Sanofi/Regeneron
Chronic Spontaneous Urticaria Emerging Drugs Profile
- Remibrutinib (LOU064): Novartis Pharmaceuticals
- TEZSPIRE (tezepelumab): AstraZeneca/Amgen
- Rilzabrutinib (SAR444671): Sanofi
Get In-Depth Knowledge on Chronic Spontaneous Urticaria Market Trends and Forecasts with DelveInsight @ Chronic Spontaneous Urticaria Treatment Market
Chronic Spontaneous Urticaria Therapeutics Market Landscape
Chronic spontaneous urticaria is a chronic condition characterized by the recurrent appearance of hives or wheals on the skin. It is a disturbing allergic condition of the skin, where symptoms persist for more than 6 weeks. The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.
Chronic Spontaneous Urticaria Market Outlook
Chronic spontaneous urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.
Chronic Spontaneous Urticaria Companies
Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
Download DelveInsight’s Chronic Spontaneous Urticaria Market report today and stay ahead in this rapidly evolving field. @ Chronic Spontaneous Urticaria Clinical Trials
Scope of the Chronic Spontaneous Urticaria Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Chronic Spontaneous Urticaria Companies- Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
- Chronic Spontaneous Urticaria Therapies- Barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
- Chronic Spontaneous Urticaria Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Chronic Spontaneous Urticaria Unmet Needs, KOL's views, Analyst's views, Chronic Spontaneous Urticaria Market Access and Reimbursement
Table of Content
1. Key Insights
2. Report Introduction
4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market
5. Executive Summary of Chronic Spontaneous Urticaria
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Chronic Spontaneous Urticaria: Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT
15. Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
